Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Where Will CNS Drug Development Go In 2018?

Aug 17 2017

• By Lucie Ellis-Taitt

GoldKeyInPuzzle_1200x675 — Unlocking new opportunities: CNS field is poised for a breakthrough

Related Content

Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

Feb 12 2015

Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash

Aug 26 2016

Related Companies

Denali Therapeutics Inc.

Yumanity Therapeutics, Inc.

Voyager Therapeutics, Inc

Sanofi

Sanofi Genzyme

Lysogene SA

BrainVectis

Johnson & Johnson

Merck KGaA

Asceneuron SA

Navitor Pharmaceuticals, Inc.

Tetra Therapeutics

BlackThorn Therapeutics, Inc.

Rodin Therapeutics, Inc.

Additional Topics

Business Strategies Market Intelligence Commercial Companies Neurology BioPharmaceutical

More from Neurological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window